- Home
- BWB vs ARVN Comparison
BWB vs ARVN Comparison
Compare BWB & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWB
- ARVN
- Stock Information
- Founded
- BWB 2005
- ARVN 2015
- Country
- BWB United States
- ARVN United States
- Employees
- BWB N/A
- ARVN N/A
- Industry
- BWB Major Banks
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- BWB Finance
- ARVN Health Care
- Exchange
- BWB Nasdaq
- ARVN Nasdaq
- Market Cap
- BWB 442.3M
- ARVN 456.2M
- IPO Year
- BWB 2018
- ARVN 2018
- Fundamental
- Price
- BWB $16.68
- ARVN $7.69
- Analyst Decision
- BWB Strong Buy
- ARVN Buy
- Analyst Count
- BWB 2
- ARVN 22
- Target Price
- BWB $20.00
- ARVN $20.21
- AVG Volume (30 Days)
- BWB 43.5K
- ARVN 1.4M
- Earning Date
- BWB 10-22-2025
- ARVN 10-29-2025
- Dividend Yield
- BWB N/A
- ARVN N/A
- EPS Growth
- BWB 12.01
- ARVN N/A
- EPS
- BWB 1.21
- ARVN N/A
- Revenue
- BWB $119,312,000.00
- ARVN $372,800,000.00
- Revenue This Year
- BWB $35.51
- ARVN $4.87
- Revenue Next Year
- BWB $11.83
- ARVN N/A
- P/E Ratio
- BWB $13.69
- ARVN N/A
- Revenue Growth
- BWB 12.23
- ARVN 299.57
- 52 Week Low
- BWB $11.93
- ARVN $5.90
- 52 Week High
- BWB $17.66
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- BWB 59.02
- ARVN 52.22
- Support Level
- BWB $16.30
- ARVN $7.58
- Resistance Level
- BWB $16.69
- ARVN $8.23
- Average True Range (ATR)
- BWB 0.35
- ARVN 0.38
- MACD
- BWB 0.03
- ARVN 0.01
- Stochastic Oscillator
- BWB 98.72
- ARVN 42.02
About BWB Bridgewater Bancshares Inc.
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering them a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.